Stock Taper
SCREENER COMPARE ANY 2 STOCKS
VOR
VOR BIOPHARMA INC.
NASDAQ
$24.24
▼ DOWN 2.10% (-0.52)

KEY STATISTICS

Market Cap$1.31 B
52w High$49.95
52w Low$6.50
Dividend Yield—
Frequency—
P/E-7.67
Volume538.76K
Shares Out.54.19M

COMPANY

LEADERSHIP

Jean-Paul Kress
CHIEF EXECUTIVE
Jean-Paul Kress

COMPENSATION 2026

Salary$515,026
Stock Awards$184,250
Incentive Plan Pay$0
All Other Comp.$1,488,224
Total$3,364,395

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 5, 2021
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
76

PRICE TARGET

Target High$31.00
Target Low$27.00
Target Median$29.00
Target Consensus$29.00

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.—
NOV
12
THU

SPLIT RECORD

DATETYPERATIO
2025-09-19Reverse1:20

PRICE

$24.24 ▼ DOWN 2.10% (−$0.52)
OVERLAYS
$24.00$24.15$24.30$24.459:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM24.24

About Vor Biopharma Inc.

https://www.vorbio.com ↗

Vor Biopharma, Inc. is a clinical-stage biotech developing engineered hematopoietic stem cell therapies, like VOR33 for AML, with collaborations for manufacturing, based in Cambridge, MA.

INDUSTRY

Biotechnology

A PRODUCT VOR BIOPHARMA INC. IS KNOWN FOR

Telitacicept
Telitacicept

Telitacicept, now Vor Biopharma's lead candidate, is a dual-target fusion protein in Phase 3 trials for autoimmune diseases.

COMPETITORS

COMPETITOR
ALLO COMPARE
CRSP COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
99
LISTED HERE
17
RANKED BY POSITION SIZE
XBI
0.37% · 1.8M
VTI
0.00% · 1.6M
XSU.TO
0.03% · 1.0M
FESM
0.04% · 120.2K
SBIO
0.63% · 66.5K
LABU
0.24% · 62.5K
XRS2.DE
0.03% · 37.3K
FSCC
0.19% · 30.6K
OMFS
0.23% · 28.6K
BBC
0.98% · 21.8K
RSSL
0.03% · 19.6K
RTWP.L
0.04% · 4.0K
ACSG
0.12% · 2.8K
BIB
0.04% · 1.9K
PWS
0.07% · 815
RESM
0.04% · 106
USFMDN.MX
0.00% · 92

INSTITUTIONAL OWNERSHIP

SHARES OWNED
59.47%
HOLDERS
93
TOP 12 OF 93 · RANKED BY POSITION SIZE
Tcg Crossover Management, LLC
5.7M sh · $96.5M
Ra Capital Management, L.P.
5.4M sh · $96.43M
Fcpm Iii Services B.V.
4.1M sh · $73.45M
Vr Adviser, LLC
3.0M sh · $54.26M
Frazier Life Sciences Management, L.P.
2.5M sh · $33.27M
Fmr LLC
2.5M sh · $33.04M
Caligan Partners LP
1.9M sh · $34.34M
Great Point Partners LLC
1.8M sh · $31.22M
Paradigm Biocapital Advisors LP
1.8M sh · $31.22M
Cowen And Company, LLC
1.2M sh · $854.41K
Marshall Wace, Llp
1.2M sh · $20.57M
State Street Corp
1.1M sh · $19.95M

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity1
Return On Assets5
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
10 PERCENT OWNER
RA CAPITAL MANAGEMENT, L.P.
Purchase · 1.5K shares
2026-08-24
★
10 PERCENT OWNER
RA CAPITAL MANAGEMENT, L.P.
Sale · 1.5K shares
2026-08-24
★
10 PERCENT OWNER
RA CAPITAL MANAGEMENT, L.P.
Purchase · 2.1M shares
2026-07-16
★
10 PERCENT OWNER
RA CAPITAL MANAGEMENT, L.P.
Sale · 2.1M shares
2026-07-16

MOST RECENT ANALYST GRADES

GRADE SUMMARY
NEUTRAL 1
BUY 1
OVERWEIGHT 1
OUTPERFORM 1
4 GRADES IN THE LAST 12 MONTHS
Wedbush NEUTRAL HC Wainwright & Co. BUY JP Morgan OVERWEIGHT Baird OUTPERFORM

SECTORS PEERS

PEERPRICE
FBRX$76.99COMPARE
ALEC$2.56COMPARE
FATE$2.41COMPARE
PEPG$3.15COMPARE
NKTX$2.77COMPARE
ANIX$3.04COMPARE
SPRO$1.23COMPARE
MCRB$5.75COMPARE